#1 Clinical Trials Search in Europe

Tofogliflozin

Tofogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is being studied in clinical trials for its potential benefits in managing type 2 diabetes mellitus and related conditions such as diabetic kidney disease and non-alcoholic fatty liver disease. These trials aim to evaluate the drug’s efficacy, safety, and long-term effects when used alone or in combination with other treatments like insulin or GLP-1 analogues.

Table of Contents

What is Tofogliflozin?

Tofogliflozin, also known by the brand names Apleway and Deberza, is a medication primarily used to treat type 2 diabetes mellitus[1]. It belongs to a class of drugs called SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors)[2]. These medications work in a unique way to help control blood sugar levels in people with diabetes.

How Does Tofogliflozin Work?

Tofogliflozin works by blocking a protein in the kidneys called SGLT2. This protein is responsible for reabsorbing glucose (sugar) from the urine back into the bloodstream. By inhibiting SGLT2, tofogliflozin causes more glucose to be excreted in the urine, which helps lower blood sugar levels[2]. This mechanism of action is different from other diabetes medications, which often work by affecting insulin production or sensitivity.

Conditions Treated by Tofogliflozin

Tofogliflozin is primarily used to treat:

  • Type 2 Diabetes Mellitus: This is the main condition for which tofogliflozin is prescribed. It helps control blood sugar levels in adults with type 2 diabetes[1].
  • Diabetic Kidney Disease (DKD): Research is being conducted to evaluate the effectiveness of tofogliflozin in treating kidney problems associated with diabetes[2].
  • Non-alcoholic Fatty Liver Disease (NAFLD): Studies are exploring the potential benefits of tofogliflozin in patients with NAFLD, a condition often associated with type 2 diabetes[3].

How is Tofogliflozin Administered?

Tofogliflozin is typically administered as follows:

  • It comes in tablet form and is taken orally (by mouth)[1].
  • The usual dose is 20 mg once daily, taken before or after breakfast[2].
  • Treatment duration can vary, with some studies evaluating its use for up to 52 weeks or longer[4].

Efficacy of Tofogliflozin

Clinical trials have shown that tofogliflozin can be effective in several ways:

  • Glycemic Control: It helps reduce HbA1c levels, which is a measure of average blood sugar over the past 2-3 months[1].
  • Weight Loss: Many patients experience a reduction in body weight while taking tofogliflozin[1].
  • Blood Pressure: It may help lower both systolic and diastolic blood pressure[4].
  • Kidney Function: Research is ongoing to determine its effects on kidney health, particularly in reducing urine albumin-to-creatinine ratio (UACR), which is a marker of kidney damage[2].

Potential Side Effects and Safety

As with all medications, tofogliflozin can cause side effects. Common side effects may include:

  • Urinary tract infections
  • Genital infections
  • Increased urination
  • Dehydration

Long-term safety studies are ongoing to fully understand the safety profile of tofogliflozin[1]. It’s important to discuss potential risks and benefits with your healthcare provider.

Tofogliflozin in Combination Therapy

Tofogliflozin is often studied and used in combination with other diabetes medications:

  • With Insulin: It can be used as an add-on treatment to insulin therapy[1].
  • With GLP-1 Analogues: Combination therapy with GLP-1 analogues (another type of diabetes medication) is being studied for potential benefits[4].
  • Compared to Metformin: Studies are comparing the effects of tofogliflozin to metformin, a common first-line treatment for type 2 diabetes[2].

Ongoing Research and Future Prospects

Researchers are continually studying tofogliflozin to understand its full potential. Current areas of investigation include:

  • Its effects on liver health in patients with non-alcoholic fatty liver disease (NAFLD)[3].
  • Long-term safety and efficacy in combination with other diabetes medications[4].
  • Its potential benefits for kidney function in patients with diabetic kidney disease[2].

These ongoing studies may reveal new uses and benefits of tofogliflozin in the future, potentially expanding its role in diabetes management and related conditions.

Aspect Details
Drug Name Tofogliflozin (also known as DEBERZA, APLEWAY)
Drug Class SGLT2 inhibitor
Conditions Studied Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Non-alcoholic Fatty Liver Disease
Dosage in Trials 20 mg once daily, orally
Primary Outcomes Changes in HbA1c, Urine Albumin-to-Creatinine Ratio (UACR)
Secondary Outcomes Body weight, blood pressure, liver enzymes, metabolic markers, kidney function
Combination Therapies Insulin, GLP-1 analogues
Comparator Drugs Metformin, Glimepiride (sulfonylurea)
Trial Durations 16 to 104 weeks

FAQ

  • What is Tofogliflozin and how does it work? Tofogliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by reducing the reabsorption of glucose in the kidneys, leading to increased glucose excretion in urine and lowering blood sugar levels in people with type 2 diabetes.
  • What conditions are being studied with Tofogliflozin in clinical trials? Clinical trials are investigating Tofogliflozin for type 2 diabetes mellitus, diabetic kidney disease, and non-alcoholic fatty liver disease (NAFLD).
  • How is Tofogliflozin administered in these trials? In the trials, Tofogliflozin is typically administered orally as a 20 mg tablet once daily, usually before or after breakfast.
  • What are some of the key outcomes being measured in Tofogliflozin trials? Key outcomes include changes in HbA1c levels, urine albumin-to-creatinine ratio (UACR), body weight, blood pressure, liver enzymes, and various metabolic markers. Some trials also assess liver histology and kidney function.
  • Are there any combination therapies being studied with Tofogliflozin? Yes, some trials are studying Tofogliflozin in combination with other treatments such as insulin, GLP-1 analogues, and comparing it to drugs like metformin and glimepiride.

Ongoing Clinical Trials on Tofogliflozin

  • Study on the Effects of Pemafibrate and Tofogliflozin in Patients with Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis

    Not recruiting

    1
    Investigated drugs:
    Bulgaria Spain

Glossary

  • SGLT2 inhibitor: A class of medications that work by preventing the kidneys from reabsorbing glucose, leading to increased glucose excretion in urine and lower blood sugar levels.
  • HbA1c: Glycated hemoglobin, a measure of average blood sugar levels over the past 2-3 months, used to diagnose and monitor diabetes.
  • Urine Albumin-to-Creatinine Ratio (UACR): A test that measures the amount of albumin in urine compared to creatinine, used to detect early signs of kidney damage.
  • eGFR: Estimated glomerular filtration rate, a measure of kidney function that estimates how well the kidneys are filtering waste from the blood.
  • Non-alcoholic Fatty Liver Disease (NAFLD): A condition where excess fat accumulates in the liver of people who drink little or no alcohol, often associated with obesity and type 2 diabetes.
  • GLP-1 analogue: A type of medication that mimics the action of glucagon-like peptide-1, helping to regulate blood sugar levels and reduce appetite.
  • Metformin: A common first-line medication for type 2 diabetes that helps reduce glucose production in the liver and improves insulin sensitivity.
  • Sulfonylurea: A class of diabetes medications that stimulate the pancreas to produce more insulin, such as glimepiride.

References

  1. https://clinicaltrials.gov/study/NCT02201004
  2. https://clinicaltrials.gov/study/NCT05469659
  3. https://clinicaltrials.gov/study/NCT02649465
  4. https://clinicaltrials.gov/study/NCT02537834